Daxdilimab is under clinical development by Horizon Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Daxdilimab’s likelihood of approval (LoA) and phase transition for Dermatomyositis took place on 04 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Daxdilimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Daxdilimab overview

Daxdilimab (VIB-7734, MEDI-7734) is under development for the treatment of type I interferon-mediated autoimmune diseases including systemic lupus erythematosus, cutaneous lupus erythematosus, dermatomyositis, lupus nephritis and alopecia areata. It is administered through intravenous and subcutaneous route. It is a monoclonal antibody that binds to an extracellular domain of human ILT7. The drug candidate is developed based on dendritic cell platform.

It was also under development for COVID-19-related pneumonia and acute lung injury and polymyositis, Sjogren's syndrome, systemic sclerosis. 

Horizon Therapeutics overview

Horizon Therapeutics formerly Horizon Pharma, is a pharmaceutical company, which develops and commercializes medical products for the treatment of rare, autoimmune, arthritis and severe inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. A few of the company’s marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Pennsaid, Procysbi, Quinsair, Ravicti, Rayos, Tepezza, Uplinza, and Vimovo. Horizon Therapeutics provides products and services to patients and healthcare professionals in the US. The company operates through offices in the US, Switzerland, Luxembourg, Bermuda, Germany, Canada, and Israel. Horizon Therapeutics is headquartered in Dublin, Ireland.

Quick View Daxdilimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Daxdilimab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Immunology
  • Infectious Disease
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.